Congress Asset Management Co. MA Boosts Position in Alexion Pharmaceuticals, Inc. (ALXN)

Congress Asset Management Co. MA boosted its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,366 shares of the biopharmaceutical company’s stock after purchasing an additional 1,338 shares during the quarter. Congress Asset Management Co. MA’s holdings in Alexion Pharmaceuticals were worth $4,827,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jennison Associates LLC boosted its holdings in Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after acquiring an additional 4,682,336 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Alexion Pharmaceuticals by 4,509.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after acquiring an additional 864,967 shares during the last quarter. USA Financial Portformulas Corp purchased a new position in Alexion Pharmaceuticals during the 3rd quarter worth $3,632,000. IFC Holdings Incorporated FL purchased a new position in Alexion Pharmaceuticals during the 3rd quarter worth $861,000. Finally, Factory Mutual Insurance Co. boosted its holdings in Alexion Pharmaceuticals by 104.5% during the 4th quarter. Factory Mutual Insurance Co. now owns 358,500 shares of the biopharmaceutical company’s stock worth $42,873,000 after acquiring an additional 183,200 shares during the last quarter. 94.41% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have issued reports on the stock. Leerink Swann reaffirmed a “buy” rating and set a $169.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, December 6th. Raymond James Financial reaffirmed an “outperform” rating and set a $130.00 price objective (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada lifted their price objective on shares of Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $153.10.

In other news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the sale, the chief executive officer now directly owns 36,172 shares in the company, valued at approximately $4,399,600.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.35% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $119.32 on Thursday. The company has a market capitalization of $26,660.00, a price-to-earnings ratio of 53.27, a PEG ratio of 1.06 and a beta of 1.17. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96.

COPYRIGHT VIOLATION WARNING: “Congress Asset Management Co. MA Boosts Position in Alexion Pharmaceuticals, Inc. (ALXN)” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://transcriptdaily.com/2018/02/01/congress-asset-management-co-ma-boosts-position-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply